Business context and reporting period
This is Novelos Therapeutics, Inc.’s Form 10-Q for the quarter and nine months ended September 30, 2011, filed November 7, 2011. Although the request identifies Cellectar Biosciences, the filing’s registrant is Novelos Therapeutics; Novelos acquired Cellectar on April 8, 2011. The transaction was accounted for as a reverse acquisition, with Cellectar treated as the accounting acquirer, so the 2011 results include Cellectar before the closing and the combined company afterward. Comparisons with 2010 are therefore not fully like-for-like.
The company is a development-stage cancer-drug company with no product revenue. Following the acquisition, it focused on Cellectar’s cancer-targeting compounds COLD, HOT and LIGHT; development of Novelos’s NOV-002 and NOV-205 was suspended.
Financial and operating highlights
| Metric | Period / date | Reported result |
|---|---|---|
| Revenue | Three and nine months ended September 30, 2011 | No product revenue reported |
| Research and development expense | Q3 2011; Q3 2010 | $1.006 million; $0.500 million |
| General and administrative expense | Q3 2011; Q3 2010 | $0.905 million; $0.107 million |
| Net loss | Q3 2011; Q3 2010 | $1.909 million; $0.700 million |
| Net loss per share | Q3 2011; Q3 2010 | $0.07; $0.05 |
| Net loss | Nine months 2011; nine months 2010 | $5.470 million; $4.098 million |
| Operating cash use | Nine months 2011; nine months 2010 | $4.435 million; $3.269 million |
| Cash and cash equivalents | September 30, 2011 | $1.591 million |
| Working capital | September 30, 2011 | $1.587 million |
| Total assets / stockholders’ equity | September 30, 2011 | $6.995 million / $5.897 million |
| Debt and lease obligations | September 30, 2011 | $450,000 long-term notes; $6,862 capital lease obligations; no convertible debt |
For the nine months, R&D expense declined 7% year over year, while G&A expense rose 80%; total costs and expenses increased to $5.019 million from $3.631 million. The quarterly loss widened as research activity resumed and post-acquisition staffing, stock compensation and public-company costs increased. Nine-month net loss also included $746,207 of merger costs and a $66,820 loss on derivative warrants.
Cash increased from $673,739 at December 31, 2010, supported in part by $4.866 million of net proceeds from the April private placement and $905,649 of cash acquired in the transaction. The company used $675,743 to repay long-term obligations during the nine months, including settling a bank note; $500,000 of restricted cash was released. The $450,000 Wisconsin Department of Commerce notes are deferred-payment debt, with principal and interest payments scheduled to begin in 2015.
Outlook, risks and unusual items
- Management said September 30 cash was expected to fund operations only through the end of 2011. Continued operations depended on obtaining additional financing; no assurance was given that financing would be available.
- The company had filed an S-1 for a proposed underwritten offering of up to $15 million, excluding any underwriter over-allotment, but it was not yet effective. The filing does not provide a completed offering or updated post-period cash runway.
- Management planned to begin a Phase 1b HOT dose-escalation trial in Q4 2011 and investigator-sponsored Phase 1/2 LIGHT imaging trials in Q4 2011; Phase 2 HOT trials were expected in 2012. It expected to submit a COLD IND application in late 2012. These were plans, not reported outcomes.
- The company expected continuing operating losses and identified financing needs, clinical and preclinical development, regulatory clearance, manufacturing, competition and product-development failure as significant risks.
- The April 2011 acquisition generated a provisional $1.675 million excess of purchase price over net assets acquired; the allocation to intangibles and goodwill remained subject to final valuation and could change materially.
- Investors in the April private placement had registration rights. The filing described potential liquidated damages if registration deadlines were missed; on November 3, 2011, investors agreed to extend the deadlines in relation to a contemplated public offering. No damages accrual was recorded.
- A securities class action concerning alleged disclosures about the former NOV-002 trial remained pending; defendants had moved to dismiss the second amended complaint. In the BAM dispute over NOV-002-related technology rights, the court ruled for the company in October 2011 and dismissed BAM’s counterclaims, subject to its right to seek post-judgment relief or appeal.
- The company reported that disclosure controls were effective as of September 30, 2011 and that no material change in internal control over financial reporting was identified during the quarter.
Important facts for investors to verify
- Confirm the issuer identity and reverse-acquisition accounting: this filing is for Novelos Therapeutics, with Cellectar as accounting acquirer.
- Verify subsequent financing, cash balance and actual runway; management’s stated runway extended only through year-end 2011.
- Check whether the proposed offering became effective and closed, and whether registration-related obligations or damages arose.
- Track actual trial starts and regulatory progress against the stated HOT, LIGHT and COLD timelines.
- Review the final acquisition purchase-price allocation, the status of the class action, and any appeal or further developments in the BAM matter.